Syncona Once More Proves Commitment to Freeline in Series B Funding Round
June 20, 2018
Source: Fierce Biotech
591
Syncona has once again proven its commitment to gene therapy start-up, Freeline Therapeutics with a £85 million investment from the £88 million series B funding round. Freeline’s main focus is on gene therapy for Haemophilia B and Farby disease and this latest cash injection ensures Syncosa’s majority stake in the startup.
Freeline was established towards the end of 2015 when Syncona committed £25 million in their A series funding round. They initially started with gene therapy technology from the London University UCL and later went on to buy an adeno-associated virus manufacturing platform which was once again funded by Syncona bringing the total of the series A funding to £3.4 million.
Syncona’s dedication is rooted in the scientific reputation of the people involved. Freeline was founded by Syncona and UCL business in order to further develop UCL professor Amit Nathwani, M.D., Ph.D.’s AAV gene therapy platform. The AVV vector is anticipated to result in the liver’s stable and long-lasting production of therapeutic proteins.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- Why Small Biotech Needs To Plan Ahead For Global Reach April 6, 2022
- Drugdu.com’s 4 most Popular Veterinary APIs and Veterinary medicine Suppliers September 6, 2018
- 4 Pharmaceutical Machinery Packaging and Materials Suppliers September 6, 2018
- 3 ENT Equipment and Medical Anaesthesia Equipment Suppliers September 6, 2018
- Need Natural Plant Extracts? Here are 4 Suppliers! September 6, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
